Phase III comparative study of KRP-108 -Open-label, active-controlled, crossover comparative study of KRP-108 in pediatric bronchial asthma-

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Formoterol/fluticasone propionate (Primary) ; Fluticasone propionate; Salmeterol
Indications Asthma
Focus Therapeutic Use
Sponsors Kyorin Pharmaceutical

29 Jun 2020 According to a Kyorin Pharmaceutical media release, the company has received approval form the Ministry of Health, Labour and Welfare for a partial change in dosage and administration to add an indication for the pediatric use of Flutiform 50 Aerosol - 56 inhalations and Flutiform 50 Aerosol - 120 inhalations, a combination drug for asthma treatment.
03 Aug 2018 Status changed from recruiting to active, no longer recruiting.
01 Aug 2017 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com